Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 1948

Next Previous
Search
Drug Profile

ASP 1948

Alternative Names: ASP-1948; PTZ-329

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Potenza Therapeutics
  • Developer Astellas Pharma; Potenza Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 27 Apr 2023 Astellas Pharma in collaboration with Merck completes phase I trial in Solid tumours (Metastatic disease) in USA, United Kingdom, Taiwan, Portugal, Spain, South Korea, Canada, Japan, Italy (IV) (NCT03565445)
  • 11 Feb 2022 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) (Astellas pipeline, February 2022)
  • 11 Feb 2022 Discontinued - Phase-I for Solid tumours (Metastatic disease) in USA, United Kingdom, Taiwan, Portugal, Spain, South Korea, Canada, Japan, Italy (IV) (Astellas pipeline, February 2022)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top